Tocagen Phase III study in brain cancer fails, sending shares plummeting
The company said Thursday morning that its study failed to meet its primary endpoint in high-grade gliomas. Shares of the company fell more than 80 percent on the Nasdaq.
What’s the fate of BeiGene’s PD-1 inhibitor after Bristol-Myers Squibb’s buyout of Celgene?
In an interview at the ASCO meeting, BeiGene chief adviser Eric Hedrick said the company is well-prepared for when it likely regains global rights to tislelizumab.
presented by
How to Optimize Your Phlebotomy Setup for Efficient Patient Care
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
BMS’s immunotherapy drug Opdivo fails in Phase III brain cancer study
The drug was being tested in combination with radiation therapy among newly diagnosed patients with glioblastoma, a notoriously difficult-to-treat and invariably fatal disease.
BMS, Celgene tout synergies in $74B mega-deal, but Revlimid’s winter is coming
In a call to following news of the deal, executives pointed to near-term launch opportunities and pipelines, but some analysts expressed concern about the loss of patent protection for Revlimid and Opdivo.
Bristol-Myers Squibb to acquire Celgene in $74B deal
The acquisition brings together two of the largest drugmakers in the country, both of which are major players in biopharma, particularly oncology.
Vedanta Biosciences raises $27M in Series C round
The company plans to use the funding to support its various microbiome-based drug development programs in oncology, food allergy and bacterial infection.
presented by
The Top-Rated Orthopedic Surgery Centers in the Houston Area and Beyond
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.